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  In this study, the effects of subcutaneous (SC) injection of pilocarpine (a cholinomimetic agent) 
and atropine (a muscarinic receptors antagonist) were investigated on a tonic model of orofacial pain 
in rats. The contribution of the endogenous analgesic opioid system was assessed using naloxone (an 
opioid receptors antagonist). Tonic orofacial pain was induced by SC injection of a diluted formalin 
solution (1%, 50 μL) in the right upper lip, and the time spent face rubbing was measured in five min 
blocks for 1 h. Formalin induced a biphasic (first phase: 0-5 min and second phase: 15-35 min) pain 
response. Pilocarpine significantly (P < 0.05) suppressed both phases of orofacial pain. Atropine did 
not have any effect and naloxone non-significantly increased the intensity of pain when used alone. 
In  the  pre-injection  examinations,  atropine  prevented,  but  naloxone  did  not  reverse  the 
antinociceptive  effect  of  pilocarpine.  The  results  indicated  that  SC  injection  of  formalin  in  the 
orofacial region induced a marked biphasic pain. Pilocarpine via muscarinic cholinergic receptors 
produced  antinociceptive  effect  in  the  orofacial  formalin-induced  pain.  The  endogenous  opioid 
analgesic system may not have a role in pilocarpine-induced antinociception.   
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׌ناهد درد رب نیپرا֩ولیپ رثا -  شوم رد نیلامرف زا ׌شان ׌تروص ׌ئارحص ׌اه  
 هدی֩چ  
 ُذًز׌֯ تس׌ًَ֯اتًآ( ي׌پٍزتآ ٍ )֩׌صزٌ׌لَ֩ ذلقه ׌ٍراد( ي׌پراَ֩ل׌پ ׌ذلج ز׌س ق׌رشت تازثا ِعلاطه ي׌ا رد  ׌اّ  ׌ًاّد درد ֩׌ًَت لذه ֩׌ رد )׌ٌ׌را֩سَه –     تلاخد .ذض ׌سرزب ׌ترَص
 ׌اّ ُذًز׌֯ تس׌ًَ֯اتًآ( ىَسَ֩لاً سا ُدافتسا اب ׌لخاد درد ذض ׌ذ׌ئَ׌پا نتس׌س ׌ًاّد درد .ذض ׌با׌سرا )׌ذ׌ئَ׌پا -    نجح ِب ذصرد ֩׌( ي׌لاهزف ق׌قر لَلحه ׌ذلج ز׌س ق׌رشت اب ֩׌ًَت ׌ترَص 00  
 ׌ًاهس لصاَف رد ترَص ىداد صلاه ׌ازب ُذض ׌زپس ىاهس تذه ٍ ذ׌دز֯ داج׌ا لااب بل ِب )زت׌لٍز֩׌ه  ׌ا ِق׌قد جٌپ تذه رد    ֩׌    ِلحزه ٍد درد خساپ ֩׌ ي׌لاهزف .ذض تبث تعاس  :لٍا ِلحزه( ׌ا
 ׌لا زفص ق׌اقد 0    ق׌اقد :مٍد ِلحزه ٍ ِق׌قد 10    ׌لا 50  .دز֩ داج׌ا )  راد ׌ٌعه ف׌عضت بجَه ي׌پراَ֩ل׌پ ( 00 / 0 P <  )   ׌ًاّد درد ِلحزه ٍد زّ –    ٍ ي׌پٍزتآ سا ׌ئاٌْت ِب ُدافتسا رد .ذض ׌ترَص
 ىَسَ֩لاً ٍ تضاذً֯ زثا درد تذض زب ي׌پٍزتآ ،ىَسَ֩لاً ىآ   ه ز׌غ رَط ِب ار  ار ىآ ىَسَ֩لاً ׌لٍ دز֩ راْه ار ي׌پراَ֩ل׌پ ׌درد ذض زثا ي׌پٍزتآ ،ق׌رشت ص׌پ ׌اّ ص׌اهسآ رد  .داد ص׌اشفا راد ׌ٌع
د ِ׌حاً رد ي׌لاهزف ׌ذلج ز׌س ق׌رشت ِ֩ ذًداد ىاطً ج׌اتً .دَوًٌ سَ֩عه ّ ׌ًا –    داج׌ا صخطه ِلحزه ٍد اب درد ֩׌ ׌ترَص ذٌ֩ ׌ه  .  ׌درد ذض زثا ي׌پراَ֩ل׌پ   ّد درد رد ׌ًا –   ي׌لاهزف سا ׌ضاً ׌ترَص  
׌ز֯ ِطساٍ اب    ֩׌صزٌ׌لَ֩ ׌ٌ׌را֩سَه ׌اّ ُذًز׌֯  .ذضاب ِتضاذً ׌طقً ي׌پراَ֩ل׌پ درد ذض لوع رد تسا ي֩وه ׌لخاد ׌ذ׌ئَ׌پا درد ذض نتس׌س .ذسر ׌ه ماجًا ِب  
:׌دیل֩ ׌اه هژاو   ׌ًاّد درد ،ىَسَ֩لاً ،ي׌پٍزتآ ،ي׌پراَ֩ل׌پ –   ׌ئازحص شَه ،׌ترَص  
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Introduction 
 
The  orofacial  region  is  one  of  the  most  densely 
innervated (e.g. the trigeminal nerve) areas of the body, 
which focuses some of the most common acute pain, i.e. 
those accompanying  the pathological states of  the  teeth 
and the related structures. It is also the site of frequent 
chronic  (post-herpetic  neuralgia  and  migraine)  and 
referred pain.1 The orofacial formalin test was introduced 
as  a  tonic  model  of  pain,2  and  thereafter  has  been 
frequently used with success in the study of modulating 
mechanisms of orofacial pain.3-5 
The  role  of  acetylcholine,  cholinergic  agonists  and 
cholinesterase  inhibitors,  collectively  termed  cholino-
mimetics, in the modulation of pain and analgesia has been 
established.6  Although  there  is  no  report  showing  the 
effect  of  systemic  injection  of  pilocarpine  on  pain,  the 
involvement of other cholinomimetics such as physostig-
mine, neostigmine on pain and analgesia was reported.7,8 
Moreover,  the  antinociceptive  effects  induced  by  intra-
hippocampal  and  intra-dentate  gyrus  administration  of 
pilocarpine were reported.9,10   
Naloxone is a competitive antagonist of mu and kappa 
receptors with higher affinity for mu receptors.11 Naloxone 
has been used to explore the involvement of endogenous 
opioid system in the rat model of orofacial region pain.12-14  
The aim  of  the  present study was  to  investigate  the 
effects of pilocarpine and atropine on the orofacial pain 
induced  by  subcutaneous  injection  of  formalin  in  the 
upper  lip  in  rats.  Moreover,  the  involvement  of  the 
endogenous  analgesic  opioid  system  on  the  effect  of 
pilocarpine in pain was assessed with subcutaneous (SC) 
injection of naloxone. 
  
Materials and Methods 
 
Healthy  adult  male  Wistar  rats,  weighing  230-270  g 
were  used  in  this  study.  Rats  were  maintained  in 
polyethylene  cages  with  food  and  water  available  ad 
libitum, with controlled ambient temperature (23 ± 0.5 °C) 
and under a 12 h light-dark cycle (lights on at 07:00 h). Six 
rats were used in each drug treatment. Experiments were 
carried  out  between  12:00  h  and  16:00  h.  The 
experimental  protocol  was  approved  by  the  Laboratory 
Animal Care and Use Center of the Faculty of Veterinary 
Medicine of Urmia University. 
The drugs used in the present study were pilocarpine, 
atropine sulfate and naloxone dihydrochloride. All drugs 
were  purchased  from  Sigma-Aldrich  Co.,  Steinheim, 
Germany, and were dissolved in normal saline.  Pilocarpine 
at doses of 0.125, 0.25, 0.5, 1, 2, and 4 mg kg-1, atropine (1 
mg kg-1) and naloxone (1 mg kg-1) were SC injected using a 
27-gauge injection needle at the back region of the neck. 
Pilocarpine, atropine and naloxone were injected 30, 20, 
and 15 min before induction of orofacial pain, respectively. 
  The doses of pilocarpine, atropine and naloxone used in 
the present study were close to other reports.15-18 
Orofacial formalin test was used for the induction of 
pain. Before the rats were pain-tested, they were placed in 
plexiglass chambers (30 × 30 × 30 cm) for 30 min on three 
successive  days  to  minimize  stress-activated  pain 
suppressive mechanisms.19 The orofacial formalin test was 
applied as follows. Fifty microliters of 1% diluted formalin 
solution was SC injected in the right upper lip just lateral 
to the nose using a 30-gauge injection needle.5 The rat was 
placed in a chamber with a mirror mounted at 45 degrees 
angle beneath the floor to allow an unobstructed view of 
the orofacial region.  
The  time  each  animal  spent  facial  rubbing  with 
ipsilateral forepaw was recorded (using a stopwatch), in 
consecutive  5-min  bins  over  a  period  of  1  h,  and  was 
considered as an index of nociception. Formalin injection 
induced  a  stereotyped  response  characterized  by  two 
well  distinct  phases.1,5,20  In  the  present  study,  data 
collected  between  0  and  5  min  post-formalin  injection 
represented  first  (early)  phase  and  data  collected 
between  15  and  35  min  after  injection  of  formalin 
represented second (late) phase.  
Data obtained from the SC injections of normal saline 
and  formalin  were  analyzed  using  repeated  measure 
ANOVA followed by Duncan’s test. To evaluate significance 
differences among drug-treated groups, one-way analysis 
of variance (ANOVA) and Duncanۥ s test were applied. In 
figures,  all  values  are  expressed  as  the  mean  ±  SEM.  A 
value of P < 0.05 was considered statistically significant. 
 
Results 
 
The SC injection of normal saline into the rat upper lip 
produced a negligible nociceptive response only in the first 
5-min block (Fig. 1). Diluted formalin, when injected SC into 
the upper lip, produced a typical pattern of face rubbing 
behavior.  Significant  differences  in  face  rubbing  were 
observed among 1st, 4th, 5th, 6th, and 7th with the other 5-min 
blocks after subcutaneous injection of formalin (P < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. The orofacial pain response induced by SC injection of 
normal saline and formalin in the upper lip in rats. Each point 
represents the mean ± SEM. (n = 6). * indicates significant difference 
compared with normal saline and other 5-min blocks (P < 0.05).  93  E. Tamaddonfard et al. Veterinary Research Forum. 2012; 3 (2) 91 - 95 
 
Therefore,  the  formalin-induced  nociceptive  behavior 
showed  a  biphasic  time  course:  the  first  phase  began 
immediately  after  formalin  injection  and  declined  in 
approximately 5 min, while the second phase began about 
15 min after formalin injection and lasted about 20 min 
and declined to the end of recording period (1 h) (Fig. 1).         
The SC injection of pilocarpine at doses of 0.125, 0.25 
mg kg-1 had no effect, whereas at doses of 0.5, 1, 2, and 4 
mg  kg-1  pilocarpine  significantly  (P  <  0.05)  suppressed 
both  phases  of  pain.  No  significant  differences  were 
observed among the antinociceptive effects induced by 0.5, 
1, and 2 mg kg-1 of pilocarpine. The antinociceptive effect 
induced by SC injection of 4 mg kg-1 of pilocarpine was 
more than that obtained from pilocarpine at doses of 0.5, 
1, and 2 mg kg-1 (Fig. 2A and 2B).  
The SC injections of atropine and naloxone at the same 
dose  of  1  mg  kg-1  alone  had  no  effect,  whereas 
pretreatment with atropine (1 mg kg-1) significantly (P < 
0.05)  blocked  the  pilocarpine-induced  antinociceptive 
effects  on  the  first  and  second  phases  of  pain.  The  SC 
injection of naloxone (1 mg kg-1) after pilocarpine (0.5 mg 
kg-1) did not reverse pilocarpine-induced antinociception 
on both phases of pain (Fig. 3A and 3B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Effect of pilocarpine on the first (A) and second (B) phases 
of formalin-induced orofacial pain. Each column represents the 
mean ± SEM. (n = 6).  * indicates significant difference compared 
with normal saline treated group (P < 0.05), † indicates significant 
difference compared with pilocarpine (0.125, 0.25, 0.5, 1, and 2 
mg kg-1) treated groups.  
 
Discussion 
 
The  present  study  shows  that  the  SC  injection  of 
formalin into the upper lip produced a distinct biphasic 
pattern in the face rubbing performed by ipsilateral 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  3.  Effects  of  atropine  and  naloxone  on  the  pilocarpine-
induced antinociception in the first (A) and second (B) phases of 
orofacial formalin test.  Each column represents the mean ± SEM. 
(n = 6). * indicates significant difference compared with other 
treated groups (P < 0.05).  
 
forepaw. The SC injection of formalin 1.5% into the upper 
lip induced a biphasic pattern in the face rubbing in rats.21 
During the orofacial formalin test, two distinct phases due 
to different mechanisms of nociception produces the first 
phase  which  is  associated  with  direct  stimulation  of  C-
nociceptors, and the second phase which is a reflection of  
integration between nociceptors and spinal and brainstem 
signaling.22 Face rubbing with the ipsilateral forepaw due 
to formalin injection into the upper lip has been mentioned 
as a specific nociceptive response.1 Vocalization, grooming 
and scratching due to electrical, mechanical, thermal and 
chemical (capsaicin, formalin) stimulation of the orofacial 
region  have  been  reported  by  some  researchers.23-26  
However, nociceptive behavior obtained from the present 
study is in agreement with other investigations.1,5,21,27,28 
The  effect  of  pilocarpine  on  the  orofacial  formalin-
induced pain, at least in the present study, was not dose 
dependent. Pilocarpine at low doses (0.125 and 0.25 mg 
kg-1)  had  no  effect.  There  was  no  significant  difference 
observed between the antinociceptive effects induced by 
pilocarpine  at  the  doses  of  0.5,  1,  and  2  mg  kg-1.  The 
antinociceptive effect produced by pilocarpine at a dose of 
4 mg kg-1 was at the highest level. Pilocarpine, as a cholino-
mimetic agent at the dose range of 1-8 mg kg-1, has been 
frequently  used  in  the  study  of  the  involvement  of  the 
cholinergic system in behavioral and physiological events 
such as jaw tremor, yawning and salivation in rats.15,16 
Therefore, the high antinociceptive response induced by 
pilocarpine  at  the  high  dose  observed  in  the  present 
study might have been associated with induction of other 
events such as tremor interfering with pain mechanisms.  94 
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In  other  words,  pilocarpine-induced  other  behaviors 
such as salivation, tremor, yawning, and defecation may be 
interrupted the pain behavior such as face rubbing. The 
preventive  effect of atropine on  the pilocarpine-induced 
antinociception produced in the present study indicated 
that  muscarinic  receptors  might  be  involved  in  the 
antinociceptive  effect  of  pilocarpine.  There  is  no  report 
describing the antinociceptive effect induced by systemic 
injection  of  pilocarpine  in  the  formalin  test  in  rats. 
However,  intra-hipocampal  and  intra-dentate  gyrus 
microinjection  of  pilocarpine  produced  antinociceptive 
effect  in  anesthetized  rats.  The  antinociceptive  effect 
induced  by  pilocarpine  was  inhibited  by  pretreatment 
with atropine.9,10  
In  the  present  study,  naloxone  non-significantly 
increased  the  pain  intensity,  and  pilocarpine-induced 
antinociception  was  not  reversed  with  naloxone.  This 
indicates  that  pilocarpine-induced  analgesia  was  not 
mediated  through  endogenous  analgesic  opioid  system. 
There  is  not  any  report  describing  the  mechanism  of 
pilocarpine-induced antinociception. The analgesic effect 
induced  by  SC  injection  of  physostigmine,  a  cholino-
mimetic agent, was not antagonized with naloxone in the 
neuropathic pain in rats.29 However, intrathecal injection 
of  physostigmine  and  neostigmine  with  morphine 
produced  synergistic  antinociceptive  effects  in  the  hot 
plate and tail immersion tests of nociception in rats.30 In 
the present study, we used the 0.5 mg kg-1 of pilocarpine in 
the  pretreatment  examinations.  This  may  be  associated 
with  the  fact  that  statistical  analysis  did  not  show  any 
significant  differences  among  the  anti-nociceptive  effects 
produced by 0.5, 1, and 2 mg kg-1 of pilocarpine. On the other 
hand, the beginning of pilocarpine-induced behaviors such 
as tremor, yawning and salivation was observed when 1 and 
2 mg kg-1 of pilocarpine was used. In this study, we observed, 
but not recorded, pilocarpine-induced behaviors including 
tremor, salivation, defecation, and yawning. 
In conclusion, results of the present study showed that 
pilocarpine,  through  muscarinic  cholinergic  receptors 
produced an antinociceptive effect in formalin-induced oro-
facial pain. The endogenous analgesic opioid system might 
not be involved in pilocarpine-induced antinociception. 
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